Stressor-induced alteration of cytokine production in multiple sclerosis patients and controls

Psychosomatic Medicine

Volumn 60, Issue 4, 1998, Pages 484-491

  Ackerman, Kurt D ^a,b   Martino, Michael ^a   Heyman, Rock ^a   Moyna, Niall M ^a   Rabin, Bruce S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cytokine production; Experimental stress; Multiple sclerosis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 4; MITOGENIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; HUMAN; MACROPHAGE; MALE; MENTAL STRESS; MOOD; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0031879945     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-199807000-00016     Document Type: Article

References (77)

1. Grant I: Psychosomatic-somatopsychic aspects of multiple sclerosis. In Hailbreich U (ed), Multiple Sclerosis: A Neuropsychiatrie Disorder. Washington, DC, American Psychiatric Press, 1993, 119-136
2. Warren S, Greenhill S, Warren KG: Emotional stress and the development of multiple sclerosis: Case-control evidence of a relationship. J Chron Dis 35:821-831, 1982
3. Grant I, Brown GW, Harris T, et al: Severely threatening events and marked life difficulties preceding onset or exacerbation of multiple sclerosis. J Neurol Neurosurg Psychiatry 52:8-13, 1989
4. Franklin GM, Nelson LM, Heaton RK: Stress and its relationship to acute exacerbations in multiple sclerosis. J Neurol Rehab 2:7-11, 1988
5. Stip E, Truelle JL: [Organic personality syndrome in multiple sclerosis and effect of stress on recurrent attacks]. [French]. Can J Psychiatry 39:27-33, 1994
6. Nisipeanu P, Korczyn AD: Psychological stress as risk factor for exacerbations in multiple sclerosis. Neurology 43:1311-1312, 1993
7. Sibley WA, Bamford CR, Clark K, et al: A prospective study of physical trauma and multiple sclerosis. J Neurol Neurosurg Psychiatry 54:584-589, 1991
8. Chelmicka-Schorr E, Arnason BG: Nervous system-immune system interactions and their role in multiple sclerosis. Ann Neurol 36(Suppl):S29-S32, 1994
9. Kuroda Y, Mori T, Hori T: Restraint stress suppresses experimental allergic encephalomyelitis in Lewis rats. Brain Res Bull 34:15-17, 1994
10. Levine S, Saltzman A: Nonspecific stress prevents relapses of experimental allergic encephalomyelitis in rats. Brain Behav Immun 1:336-341, 1987
11. Griffin AC, Lo WD, Wolny AC, et al: Suppression of experimental autoimmune encephalomyelitis by restraint stress: Sex differences. J Neuroimmunol 44:103-116, 1993
12. The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661, 1993
13. Liblau RS, Singer SM, McDevitt HO: Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 16:34-38, 1995
14. Panitch HS: Interferons in multiple sclerosis. A review of the evidence. Drugs 44:946-962, 1992
15. Panitch HS, Hirsch RL, Schindler J, et al: Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 37:1097-1102, 1987
16. Olsson T: Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 45(Suppl 6):S11-S15, 1995
17. Saab PG, Matthews KA, Stoney CM, et al: Premenopausal and postmenopausal women differ in their cardiovascular and neuroendocrine responses to behavioral stressors. Psychophysiology 26:270-280, 1989
18. Turner JR, Sherwood A, Light KC: Intertask consistency of hemodynamic responses to laboratory stressors in a biracial sample of men and women. Int J Psychophysiol 17:159-164, 1994
19. Berntson GG, Cacioppo JT, Binkley PF, et al: Autonomic cardiac control. III. Psychological stress and cardiac response in autonomie space as revealed by pharmacological blockades. Psychophysiology 31:599-608, 1994
20. Sita A, Miller SB: Estradiol, progesterone and cardiovascular response to stress. Psychoneuroendocrinology 21:339-346, 1996
21. Marsland AL, Manuck SB, Fazzari TV, et al: Stability of individual differences in cellular immune responses to acute psychological stress. Psychosom Med 57:295-298, 1995
22. Llabre MM, Saab PG, Hurwitz BE, et al: The stability of cardiovascular parameters under different behavioral challenges: One-year follow-up. Int J Psychophysiol 14:241-248, 1993
23. Knapp PH, Levy EM, Giorgi RG, et al: Short-term immunological effects of induced emotion. Psychosom Med 54:133-148, 1992
24. Minden SL, Schiffer RB: Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Arch Neurol 47:98-104, 1990
25. Schubert DS, Foliart RH: Increased depression in multiple sclerosis patients. A meta-analysis. Psychosomatics 34:124-130, 1993
26. Herbert TB, Cohen S: Stress and immunity in humans: A meta-analytic review. Psychosom Med 55:364-379, 1993
27. Herbert TB, Cohen S: Depression and immunity: A meta-analytic review. Psychol Bull 113:472-486, 1993
28. Glaser R, Kiecolt-Glaser JK, Speicher CE, et al: Stress, loneliness, and changes in herpesvirus latency. J Behav Med 8:249-260, 1985
29. Kennedy S, Kiecolt-Glaser JK, Glaser R: Immunological consequences of acute and chronic stressors: Mediating role of interpersonal relationships. Br J Med Psychol 61:77-85, 1988
30. Cohen S, Tyrrell DA, Smith AP: Negative life events, perceived stress, negative affect, and susceptibility to the common cold. J Pers Soc Psychol 64:131-140, 1993
31. Poser CM, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13:227-231, 1983
32. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444-1452, 1983
33. Beck AT, Beamesderfer A: Assessment of depression: The depression inventory: Psychological measurements in psychopharmacology. In Pichot P (ed), Modern Problems in Pharmacopsychiatry. Basel, Karger, 1974, 151
34. Spielberger C, Gorsuch R, Lushene R: Manual for the State-Trait Anxiety Inventory. Palo Alto, CA, Consulting Psychologists Press, 1970
35. Beatty WW, Paul RH, Wilbanks SL, et al: Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology 45:718-723, 1995
36. Russell D, Peplau LA, Cutrona CE: The revised UCLA Loneliness Scale: concurrent and discriminant validity evidence. J Pers Soc Psychol 39:472-480, 1980
37. Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Soc Behav 24:385-396, 1983
38. McNair DM: Profile of Mood States (manual). San Diego, Education and Industrial Testing Services, 1971
39. Lepore SJ, Allen KA, Evans GW: Social support lowers cardiovascular reactivity to an acute stressor. Psychosom Med 55:518-524, 1993
40. Rao SM, Leo GJ, Bernardin L, et al: Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685-691, 1991
41. Dobbin JP, Harth M, McCain GA, et al: Cytokine production and lymphocyte transformation during stress. Brain Behav Immun 5:339-348, 1991
42. Northoff H, Weinstock C, Berg A: The cytokine response to strenuous exercise. Int J Sports Med 15(Suppl 3):S167-S171:1994
43. Schulte HM, Bamberger CM, Eisen H, et al: Systemic interleukin-1 alpha and interleukin-2 secretion in response to acute stress and to corticotropin-releasing hormone in humans. Eur J Clin Invest 24:773-777, 1994
44. Abe Y, Miyake M, Horiuchi A, et al: Changes in the productivity of cytokines and active-oxygen in peripheral blood cells following surgery. Surg Today 22:15-18, 1992
45. Redmond HP, Watson RW, Houghton T, et al: Immune function in patients undergoing open vs laparoscopic cholecystectomy. Arch Surg 129:1240-1246, 1994
46. Dugue B, Leppanen EA, Teppo AM, et al: Effects of psychological stress on plasma interleukins-1 beta and 6, C-reactive protein, tumour necrosis factor alpha, anti-diuretic hormone and serum cortisol. Scand J Clin Lab Invest 53:555-561, 1993
47. Kiecolt-Glaser JK, Marucha PT, Malarkey WB, et al: Slowing of wound healing by psychological stress. Lancet 346:1194-1196, 1995
48. Kita M, Iwaki H, Kitoh I, et al: [The effect of stress on interferon production in mice]. [French]. C R Seances Soc Biol Fil 183:282-286, 1989
49. Yamasu K, Shimada Y, Sakaizumi M, et al: Activation of the systemic production of tumor necrosis factor after exposure to acute stress. Eur Cytokine Netw 3:391-398, 1992
50. Ackerman KD, Martino M, Heyman R, et al: Immunologic response to acute psychological stress in MS patients and controls. J Neuroimmunol 68:85-94, 1996
51. Vita G, Fazio MC, Milone S, et al: Cardiovascular autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. J Neurol Sci 120:82-86, 1993
52. Anema JR, Heijenbrok MW, Faes TJ, et al: Cardiovascular autonomic function in multiple sclerosis. J Neurol Sci 104:129-134, 1991
53. Nordenbo AM, Boesen F, Andersen EB: Cardiovascular autonomic function in multiple sclerosis. J Auton Nerv Syst 26:77-84, 1989
54. Pentland B and Ewing DJ: Cardiovascular reflexes in multiple sclerosis. Eur Neurol 26:46-50, 1987
55. Neubauer B, Gundersen HJ: Analysis of heart rate variations in patients with multiple sclerosis. A simple measure of autonomic nervous disturbances using an ordinary ECG. J Neurol Neurosurg Psychiatry 41:417-419, 1978
56. Kiecolt-Glaser JK, Dura JR, Speicher CE, et al: Spousal caregivers of dementia victims: Longitudinal changes in immunity and health. Psychosom Med 53:345-362, 1991
57. Glaser R, Pearson GR, Jones JF, et al: Stress-related activation of Epstein-Barr virus. Brain Behav Immun 5:219-232, 1991
58. Imamura K, Suzumura A, Hayashi F, et al: Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 87:281-285, 1993
59. Chofflon M, Juillard C, Juillard P, et al: Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 3:523-531, 1992
60. Matsuda M, Tsukada N, Miyagi K, et al: Increased interleukin-1 production by peripheral blood mononuclear cells in patients with multiple sclerosis. J Neurol Sci 102:100-104, 1991
61. Tsukada N, Matsuda M, Miyagi K, et al: Cytotoxicity of T cells for cerebral endothelium in multiple sclerosis. J Neurol Sci 117:140-147, 1993
62. Symons JA, Bundick RV, Suckling AJ, et al: Cerebrospinal fluid interleukin l like activity during chronic relapsing experimental allergic encephalomyelitis. Clin Exp Immunol 68:648-654, 1987
63. Jacobs CA, Baker PE, Roux ER, et al: Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J Immunol 146:2983-2989, 1991
64. Gusev EI, Demina TL, Boiko AN, et al: Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: First steps towards monitoring process activity. J Neurol 241:500-510, 1994
65. Rieckmann P, Albrecht M, Kitze B, et al: Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 44:1523-1526, 1994
66. Rieckmann P, Albrecht M, Kitze B, et al Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37:82-88, 1995
67. Lu CZ, Jensen MA, Arnason BG: Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol 46:123-128, 1993
68. Beck J, Rondot P, Catinot L, et al: Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand 78:318-323, 1988
69. Huberman M, Shalit F, Roth-Deri I, et al: Decreased IL-3 production by peripheral blood mononuclear cells in patients with multiple sclerosis. J Neurol Sci 118:79-82, 1993
70. Link J, Soderstrom M, Ljungdahl A, et al: Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 44:728-734, 1994
71. Sun JB, Olsson T, Wang WZ, et al: Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 21:1461-1468, 1991
72. Panitch HS, Bever CT Jr: Clinical trials of interferons in multiple sclerosis. What have we learned?. J Neuroimmunol 46:155-164, 1993
73. Panitch HS, Hirsch RL, Haley AS, et al: Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1:893-895, 1987
74. Kuchroo VK, Das MP, Brown JA, et al: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 80:707-718, 1995
75. Racke MK, Burnett D, Pak SH, et al: Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 154:450-458, 1995
76. Racke MK, Bonomo A, Scott DE, et al: Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 180:1961-1966, 1994
77. Kennedy MK, Torrance DS, Picha KS, et al: Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 149:2496-2505, 1992